AHAM Capital launches biotechnology fund
KUALA LUMPUR: AHAM Asset Management Bhd (AHAM Capital) jas launched the AHAM World Series – Biotechnology Fund.

The fund is a wholesale feeder growth fund that provides investors access to the burgeoning opportunities within the biotechnology investment universe.

In a statement, AHAM Capital said the fund will primarily invest in the Janus Henderson Horizon Biotechnology Fund (target fund), managed by Janus Henderson.

To achieve its investment objective, the fund will allocate a minimum of 85% of its net asset value (NAV) to the target fund and a maximum of 15% to money market instruments, deposits, and/or cash.

"Biotechnology companies are at the forefront of scientific innovation, rapidly enhancing our genetic understanding to develop new treatment for major diseases. Over the past decade, we have seen significant improvements in scientific productivity, with the number of drugs receiving FDA approval doubling from 121 to 243 in the past 20 years,” AHAM Capital product solutions & customer experience chief executive Anton Tan.

“Healthcare spending is poised to increase driven by a demographic shift in the US, coupled with aging populations and globalisation. These long-term secular forces create an attractive fundamental backdrop for biotechnology investments. Despite experiencing its worst drawdown on record, the biotech sector is currently trading at a substantial discount to the broader market, presenting a unique ‘innovation on sale’ opportunity,” he added.

On outlook for the sector Janus Handerson portfolio manager Andy Acker said: “Biotechnology is currently undergoing unprecedented levels of innovation, thanks to dramatic improvements in life science tools, genetic engineering, and new modalities for treating human diseases such as cancer, autoimmune disease, and rare genetic conditions. These advancements are unearthing opportunities for investors to identify the next blockbuster (billion dollar) therapies and generate alpha for clients.”

AHAM Capital said the fund is suitable for sophisticated investors seeking capital appreciation with a medium to long-term investment horizon. The base currency of the fund is in US dollar and is available in three currency classes namely, USD Class, MYR Class, and MYR Hedged-Class.

The minimum investment amount is $10,000 for the USD class and $30,000 for the MYR class and MYR hedged-class.
Investment,AHAM Capital,Biotechnology,Anton Tan
KUALA LUMPUR: AHAM Asset Management Bhd (AHAM Capital) jas launched the AHAM World Series – Biotechnology Fund.